However, women were older and had more comorbidities than men at enrollment. Women with NSTE-ACS referred for CABG are older with more comorbidities, which is reflected by higher periproce- dural mortality, HF, bleeding, MI, and renal failure.686,695,696 Women required more periprocedural IABP, vasopressors, mechanical ventilation, dialysis, and blood products and had longer stays in the intensive care unit and hospital, higher rates of wound infection, depression, and longer recovery.549,677 An Agency for Healthcare Research and Quality metaanal- ysis of 10 RCTs through December 2011 reported no efficacy or safety difference between PCI and CABG for NSTE-ACS in men or women in 30-day or 1-year MACE (death/MI/stroke). At 2 years, the procedural success remained equal in women but favored CABG in men (P=0.002).345,564 The Agency for Healthcare Research and Quality reported similar outcomes in women with diabetes mellitus with PCI and CABG for NSTE-ACS at 7 years, but men with diabetes mellitus had fewer events with CABG. A prespecified gender analysis of the FREEDOM trial favored CABG over PCI for women with diabetes mellitus, although the difference was not as signifi- cant as it was for men.616 Consistent with the European Society of Cardiology recom- mendations, myocardial revascularization should be reserved for pregnant women with NSTE-ACS and very serious com- plications unresponsive to medical therapy.674 See Online Data Supplement 30 for more information on women. 7.8. Anemia, Bleeding, and Transfusion: Recommendations Class I 1. All patients with NSTE-ACS should be evaluated for the risk of bleeding. (Level of Evidence: C) 2. Anticoagulant and antiplatelet therapy should be weight-based where appropriate and should be ad- justed when necessary for CKD to decrease the risk of bleeding in patients with NSTE-ACS.522,697,698 (Level of Evidence: B) Class III: No Benefit 1. 